Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESQUAMATE: Neoadjuvant Pembrolizumab in cSCC
NCT05025813Phase 2Recruiting
- Sponsor
- Queensland Health
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Queensland Health. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05025813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025813.